title: [Cardiac resynchronization therapy by biventricular pacing. How many patients with left ventricular dysfunction are eligible?].
abstract: OBJECTIVE
  Cardiac resynchronization therapy by multisite biventricular pacing presents an additive therapeutic option in the treatment of severe congestive heart failure. The objective of the study was to evaluate how many patients with left ventricular dysfunction may potentially benefit from this therapy.
  
  
  METHODS
  A total of 975 patients were screened for the prevalence of left ventricular dysfunction. Patients with a left ventricular ejection fraction (LVEF) <45 % were included into the investigation. Potential benefit of biventricular pacing was presumed in the presence of: LVEF < 35 %, severe heart failure (NHYA class III or IV), intrinsic left bundle branch block pattern with QRS interval > 150 ms and the absence of atrial fibrillation in the last 3 months before study inclusion.
  
  
  RESULTS
  In 203 patients (168 male, 35 female, mean age: 64 +/- 11) an LVEF <45 % was found. A total of 12 of these patients (6 %) or 12 of 113 patients (11 %) with an LVEF <35 % were identified as appropiate candidates for biventricular resynchronization therapy.
  
  
  CONCLUSIONS
  Cardiac biventricular pacing currently serves as a therapeutic option for a relatively small subgroup of patients with left ventricular dysfunction. Focusing on estimations that the incidence of heart failure in Germany amounts to more than 100.000 cases per year our results suggest that after all more than 6.000 patients per year may potentially benefit from electric resynchronization therapy. This number may increase substantially if prospective studies can prove that patients with heart failure and atrial fibrillation or left ventricular conduction delay due to univentricular pacing also benefit from cardiac resynchronization therapy.
authors.affiliation: Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Germany. alex.yang@web.de
authors.forename: A
authors.initials: A
authors.lastname: Yang
authors.forename: C
authors.initials: C
authors.lastname: Wolpert
authors.forename: R
authors.initials: R
authors.lastname: Schimpf
authors.forename: T
authors.initials: T
authors.lastname: Schulz
authors.forename: U
authors.initials: U
authors.lastname: Krause
authors.forename: W
authors.initials: W
authors.lastname: Jung
authors.forename: S
authors.initials: S
authors.lastname: Herwig
authors.forename: K-M
authors.initials: KM
authors.lastname: Jeong
authors.forename: H
authors.initials: H
authors.lastname: Omran
authors.forename: T
authors.initials: T
authors.lastname: Lewalter
authors.forename: B
authors.initials: B
authors.lastname: Lüderitz
mesh_terms: D000368:Aged; D002037:Bundle-Branch Block / Q000628:therapy*; D002304:Cardiac Pacing, Artificial; D017147:Defibrillators, Implantable; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D013318:Stroke Volume; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000628:therapy*